GeneQuantum Healthcare (GQ), a prominent player in ADC (Antibody-Drug Conjugate) new drug development with a focus on innovative bioconjugation technologies, has recently entered into a strategic collaboration with BioMap, a leading figure in life science AI with its Foundation protein-centric Large Language Models. This collaboration aims to co-develop FIC/BIC ADC therapeutics for multiple targets, bringing together GQ's proprietary enzymatic site-specific conjugation technology platforms (iLDC® and iGDC®) and linker-payload platform with BioMap's trillion-parameter life science AI Foundation Large Language Model xTrimo and AI protein generation platform AIGP.
The collaboration agreement outlines a comprehensive approach to discovering and developing novel ADC therapies. Both companies will integrate their resources, combining BioMap's innovative target recommendation and antibody design platforms with GQ's enzymatic site-specific conjugation and linker-payload technology platforms. The collaboration will also leverage expertise in data mining, cross-model data integration and analysis, target discovery, ADC conjugation preparation, drug evaluation, indication development, and business development collaborations.
Dr. Gang Qin, Founder and Chairman of GQ, expressed excitement about the shared vision and commitment to disruptive innovation. He emphasized the collaborative and open nature of the partnership, aiming to enhance R&D efficiency, reduce development costs, and advance high-quality next-generation ADC therapeutics to address global medical needs. The goal is to bring better treatment options to patients worldwide through the integration of GQ's ADC drug development expertise with BioMap's understanding of life sciences and AI.
Ms. Vicky Qu, Senior VP of BioMap, highlighted the broad market potential in target discovery and BioMap's capabilities in immune cell activation, disease-specific target recommendation, and drug combination recommendation. She expressed honor in collaborating with GQ on next-generation ADC drugs, emphasizing the role of BioMap's Foundation Model and AIGP platform in recommending novel targets and designing high-performance antibody components. The ultimate objective is to enhance the safety and efficacy of ADC drugs by making more precise disease selections.
In conclusion, the collaboration aims to accelerate the development of breakthrough ADC therapeutics, setting a new paradigm in the global ADC drug development landscape. Both companies are optimistic about achieving significant results in diverse life science R&D scenarios by combining their generative capabilities and expertise.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!